학술논문
Three-Year Overall Survival of Patients With Advanced Non–Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study).
Document Type
Article
Author
Decroisette, Chantal; Greillier, Laurent; Curcio, Hubert; Pérol, Maurice; Ricordel, Charles; Auliac, Jean-Bernard; Falchero, Lionel; Veillon, Remi; Vieillot, Sabine; Guisier, Florian; Marcq, Marie; Justeau, Grégoire; Bigay-Game, Laurence; Bernardi, Marie; Doubre, Hélène; Pinsolle, Julian; Amrane, Karim; Chouaïd, Christos; Descourt, Renaud
Source
Journal of Immunotherapy; Jan2024, Vol. 47 Issue 1, p16-20, 5p
Subject
Language
ISSN
15249557